Search Login Register

ranibizumab (Lucentis) Summary

Description: Ranibizumab (rhuFab V2; Lucentis, Genentech, South San Francisco, CA) is a humanized monoclonal antibody fragment designed to bind all forms of VEGF, thereby blocking vessel permeability and angiogenesis in neovascular age-related macular degeneration

Also Known As: Lucentis; rhuFab V2

Networked: 1435 relevant articles (242 outcomes, 375 trials/studies) for this Drug

Key Diseases for which ranibizumab is Relevant

  1. Macular Degeneration (Age-Related Maculopathy) : 99 outcomes 183 studies in 784 results
  2. Macular Edema : 57 outcomes 77 studies in 217 results
  3. Choroidal Neovascularization : 55 outcomes 75 studies in 285 results
  4. Retinal Vein Occlusion : 19 outcomes 23 studies in 75 results
  5. Diabetic Retinopathy (Retinopathy, Diabetic) : 10 outcomes 33 studies in 65 results
Show All >>

Drugs Related to ranibizumab

  1. bevacizumab
  2. Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
  3. ranibizumab (Lucentis)
  4. aflibercept
  5. Retinaldehyde (Retinal)
  6. 1-phenyl-3,3-dimethyltriazene (PDT)
  7. verteporfin (Visudyne)
  8. pegaptanib
  9. salicylhydroxamic acid (SHAM)
  10. Dexamethasone (Maxidex)
Show All >>

Therapies Related to ranibizumab

  1. Intravitreal Injections
  2. Injections
  3. Photochemotherapy (Photodynamic Therapy)
  4. Lasers (Laser)
  5. Intraocular Injections
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.